ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
GeoVax Labs Inc

GeoVax Labs Inc (GOVX)

1.90
0.79
(71.17%)
Closed June 19 4:00PM
2.1499
0.2499
(13.15%)
After Hours: 7:59PM

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Key stats and details

Current Price
2.1499
Bid
1.66
Ask
2.49
Volume
35,646,599
1.0901 Day's Range 2.3699
1.0901 52 Week Range 10.2405
Market Cap
Previous Close
1.11
Open
1.36
Last Trade Time
Financial Volume
$ 64,556,283
VWAP
1.811
Average Volume (3m)
110,503
Shares Outstanding
2,172,272
Dividend Yield
-
PE Ratio
-0.16
Earnings Per Share (EPS)
-11.95
Revenue
-
Net Profit
-25.97M

About GeoVax Labs Inc

Geovax Labs Inc is us-based clinical-stage biotechnology company. Geovax Labs Inc is us-based clinical-stage biotechnology company.

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
Headquarters
Wilmington, Delaware, USA
Founded
1970
GeoVax Labs Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker GOVX. The last closing price for GeoVax Labs was $1.11. Over the last year, GeoVax Labs shares have traded in a share price range of $ 1.0901 to $ 10.2405.

GeoVax Labs currently has 2,172,272 shares outstanding. The market capitalization of GeoVax Labs is $4.11 million. GeoVax Labs has a price to earnings ratio (PE ratio) of -0.16.

GOVX Latest News

GeoVax Presents Data on GEO-CM04S1, a Next Generation Covid-19 Vaccine

Presentation Made During the 24th Annual World Vaccine Congress ATLANTA, GA, April 04, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company...

GeoVax to Present Data on GEO-CM04S1, a Next Generation Covid-19 Vaccine, at the World Vaccine Congress

ATLANTA, GA, March 28, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and...

GeoVax to Present at the 36th Annual Roth Conference

ATLANTA, GA, March 12, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and...

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
CMTLComtech Telecommunications Corporation
$ 4.07
(87.56%)
91.43M
NLSPNLS Pharmaceutics Ltd
$ 0.2735
(84.42%)
305.36M
ASNSActelis Networks Inc
$ 2.11
(83.48%)
51.37M
RELIReliance Global Group Inc
$ 0.40
(80.18%)
394.85M
LRHCLa Rosa Holdings Corporation
$ 1.78
(71.15%)
52.9M
STISolidion Technology Inc
$ 0.6881
(-64.35%)
16.36M
DMTKDermTech Inc
$ 0.1488
(-55.25%)
10.74M
QMCOQuantum Corporation
$ 0.3752
(-51.90%)
3.14M
ZNTLZentalis Pharmaceuticals Inc
$ 4.135
(-50.72%)
21.58M
AWINAERWINS Technologies Inc
$ 1.74
(-47.90%)
1.05M
RELIReliance Global Group Inc
$ 0.40
(80.18%)
394.85M
NLSPNLS Pharmaceutics Ltd
$ 0.2735
(84.42%)
305.36M
NVDANVIDIA Corporation
$ 135.58
(3.51%)
294.32M
MBIOMustang Bio Inc
$ 0.8517
(13.56%)
291.95M
CRKNCrown Electrokinetics Corporation
$ 0.0548
(-17.10%)
92.39M

GOVX Discussion

View Posts
tw0122 tw0122 10 hours ago
Uncle Sam $343 million and $45 million funding . Shorts running for the hills still. Shares of GeoVax (NASDAQ:GOVX) shot up 50% in mid-afternoon trading Tuesday amid news that the US government plans to fund a Phase 2b study of the company's next-generation COVID-19 vaccine.

Under the agreement, BARDA will award GeoVax up to $45M for the manufacturing of clinical materials and support for the Phase 2b study. The government will also provide around $343M for a clinical research organization to conduct the clinical trial.

Currently, the FDA has approved two mRNA COVID-19 vaccines, Pfizer (PFE) and BioNTech’s (BNTX) Comirnaty and Moderna’s (MRNA) Spikevax.




GEO-CM04S1 is currently being evaluated in three ongoing Phase 2 clinical trials:

As a primary vaccine in immunocompromised patients (with hematologic cancers receiving cell transplants or CAR-T therapy). ClinicalTrials.gov Identifier: NCT04977024. A recent presentation of unpublished data from the open-label portion of the trial indicates that GEO-CM04S1 is highly immunogenic in these patients, inducing both antibody responses, including neutralizing antibodies, and T cell responses.
As a booster vaccine in immunocompromised patients with chronic lymphocytic leukemia (CLL), a recognized high-risk group for whom current mRNA vaccines and monoclonal antibody (MAb) therapies appear inadequate relative to providing protective immunity. ClinicalTrials.gov Identifier: NCT05672355.
As a booster vaccine for healthy patients who have previously received the Pfizer or Moderna mRNA vaccine. This trial was fully enrolled in September 2023 and final results are expected in Fourth Quarter 2024, reflecting a 12-month tracking of study patients. ClinicalTrials.gov Identifier: NCT04639466.
About GeoVax

GeoVax Labs, Inc. is a clinical-stage biotechnology company developing novel therapies and vaccines for solid tumor cancers and many of the world’s most threatening infectious diseases. The company’s lead program in oncology is a novel oncolytic solid tumor gene-directed therapy, Gedeptin®, presently in a multicenter Phase 1/2 clinical trial for advanced head and neck cancers. GeoVax’s lead infectious disease candidate is GEO-CM04S1, a next-generation Covid-19 vaccine targeting high-risk immunocompromised patient populations. Currently in three Phase 2 clinical trials, GEO-CM04S1 is being evaluated as a primary vaccine for immunocompromised patients such as those suffering from hematologic cancers and other patient populations for whom the current authorized Covid-19 vaccines are insufficient, and as a booster vaccine in patients with chronic lymphocytic leukemia (CLL). In addition, GEO-CM04S1 is in a Phase 2 clinical trial evaluating the vaccine as a more robust, durable Covid-19 booster among healthy patients who previously received the mRNA vaccines. GeoVax has a leadership team who have driven significant value creation across multiple life science companies over the past several decades. For more information, visit our website: www.geovax.com.
👍️0
it_happens it_happens 14 hours ago
Wish I knew but I like the ride up.
👍️0
Awl416 Awl416 16 hours ago
What leaked?
👍️0
Monksdream Monksdream 2 months ago
GOVX new 52 week low
👍️0
Monksdream Monksdream 2 months ago
GOVX new 52 week low
👍️0
Monksdream Monksdream 3 months ago
GOVX new 52 week lo
👍️0
Muhbruh Muhbruh 4 months ago
$GOVX bottom bio recent r/s 2.48M float with $3.54 cash per share and warrants at $6.21 CEO and CFO bought at these levels this month + 13G of 9.99% from 14/02/24

''GeoVax to Present at the 2024 BIO CEO & Investor Conference at February 26, 2024, 4:15 pm ET'' pic.twitter.com/8sXy5x4gpa— STOCKS Gambino (@StocksGambino) February 26, 2024
👍️0
Monksdream Monksdream 4 months ago
GOVX new 52 week low
👍️0
Monksdream Monksdream 4 months ago
GOVX
🌈 1 🍆 1 👎️ 1 🤡 1 🩳 1
Monksdream Monksdream 4 months ago
GOVX new 52 week low
👍️0
Trompete Trompete 5 months ago
pure scam
👍️0
Monksdream Monksdream 5 months ago
GOVX new week low
👍️0
Renee Renee 5 months ago
GOVX: effective Jan. 31,2024 a one for 15 reverse split:

https://hedgefollow.com/upcoming-stock-splits.php
👍️0
GetSeriousOK GetSeriousOK 5 months ago
they've been trying for weeks to pump up the price before the R/S, but it didn't fool anyone.

Interesting to see the SP here when the dust settles after the R/S.
👍️0
silkman silkman 5 months ago
Will average down when it hits .05 again
👍️0
Monksdream Monksdream 5 months ago
GOVX new 52 week low
👍️0
Monksdream Monksdream 7 months ago
GOVX new 52 week low
👍️0
Monksdream Monksdream 8 months ago
GOVX new 52=week low
👍️0
Monksdream Monksdream 9 months ago
GOVX new 52 week low
👍️0
CarlCarlMcB CarlCarlMcB 10 months ago
Merry Christmas $$$$$$$$
👍️0
hinkydink hinkydink 10 months ago
Are you surprised?
This is a R/S dump stock.
The only ones that benefit from holding this stock are the crafty/lucky peeps or the insiders.
How long before the next R/S makes this stock look attractive to investors that don't know any better than to look past the hype?
👍️0
Monksdream Monksdream 10 months ago
GOVX new 52 week low
👍️0
81vette 81vette 11 months ago
just went to ZERO BORROW,no shares to short,never been optionable
👍️0
81vette 81vette 11 months ago
end of july,last 3 years,ran big
👍️0
CarlCarlMcB CarlCarlMcB 1 year ago
Going up river $$$$$$ FISH ON $$$$$
👍️0
Trompete Trompete 1 year ago
is this trash still listed? unbelievable
👍️0
CarlCarlMcB CarlCarlMcB 1 year ago
Lol
👍️0
XenaLives XenaLives 1 year ago
Three months with no fundamental change, the elastic on the jock strap is worn out.
👍️0
CarlCarlMcB CarlCarlMcB 1 year ago
Hold on to your jock straps $$$$$$$$
👍️0
StockLogistics StockLogistics 1 year ago
.6902 intraday gap fill this week and looking at Late Feb for next opportunity imo
👍️0
carusso carusso 1 year ago
I have no information on these important questions.
👍️0
Sprincenatu Sprincenatu 1 year ago
How soon could they do it? Do they have the money for it?
👍️0
carusso carusso 1 year ago
Develop the clinical/health applications for their patents, monetize these patents.
👍️0
Sprincenatu Sprincenatu 1 year ago
What are they expected todo next?
👍️0
carusso carusso 1 year ago
You failed to read the News...
👍️0
Trompete Trompete 1 year ago
it is hopeless, P&D on no news, will crash as always. Obsolete trash
👍️0
PennyPusher786 PennyPusher786 1 year ago
Analysts calling for a minimum of $3 and a maximum of $8!!! LET'S GET IT!

H.C. Wainwright analyst Vernon Bernardino reiterated a Buy rating on GeoVax Labs and set a price target of $8.00.

Currently, the analyst consensus on GeoVax Labs is a Moderate Buy with an average price target of $5.50

In a report released yesterday, Maxim Group also maintained a Buy rating on the stock with a $3.00 price target.
👍️0
DK11 DK11 1 year ago
Really nice here.
👍️0
KellySueNews KellySueNews 1 year ago
https://www.marketscreener.com/amp/quote/stock/GEOVAX-LABS-INC-112977270/news/GeoVax-Receives-Notice-of-Allowance-for-Zika-Vaccine-Patent-42811350/
👍️0
TheRealMrPirate TheRealMrPirate 2 years ago
Ya I've heard that, and they're over 400 different strains of the flu too...I mean Covid, you know...variants...lol
👍️ 1
La Dolce Vita La Dolce Vita 2 years ago
Might want to check your information. The Sudan Ebola virus is not the same as the Zaire Ebola virus. There are biological differences and as such the vaccines aren't interchangeable.

GOVX
👍️0
TheRealMrPirate TheRealMrPirate 2 years ago
In the works? The Ebola vaccine was already developed back in 2019'
👍️0
Trompete Trompete 2 years ago
is this trash still listed????
👍️0
gr8investment gr8investment 2 years ago
Ebola is spreading, they have the vax in the works...nuff said
👍️0
subslover subslover 2 years ago
GeoVax to Host Third Quarter 2022 Business Update and Financial Results Conference Call on November 9, 2022
October 26 2022 - 09:00AM
GlobeNewswire Inc.
Alert
Print
Share On Facebook

via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing immunotherapies and vaccines for cancer and infectious diseases, announced today that it will report third quarter 2022 financial results after the market close on Wednesday, November 9, 2022.
Following the release, management will host a live conference call and webcast to provide a general business update and discuss financial results. Subsequent to management’s prepared remarks, there will be a Q&A period for analysts and others.

Wednesday, November 9, 2022, 4:30 PM EST

Domestic: 877-269-7756

International: 201-689-7817

Conference ID: 13733113

Webcast: GeoVax Earnings Webcast

A webcast replay of the call will be available via the same link as the live webcast approximately one hour after the end of the call through February 9, 2023. A telephonic replay of the call can be accessed by calling 877-660-6853 (domestic) or 201-612-7415 (international), using access code 13733113. The telephonic replay will be available until November 23, 2022.

About GeoVax

GeoVax Labs, Inc. is a clinical-stage biotechnology company developing novel therapies and vaccines for cancers and many of the world’s most threatening infectious diseases. The company’s lead program in oncology is a novel oncolytic solid tumor gene-directed therapy, Gedeptin®, presently in a multicenter Phase 1/2 clinical trial for advanced head and neck cancers. GeoVax’s lead infectious disease candidate is GEO-CM04S1, a next-generation COVID-19 vaccine targeting high-risk immunocompromised patient populations. Currently in two Phase 2 clinical trials, GEO-CM04S1 is being evaluated as a single-dose, COVID-19 vaccine for immunocompromised patients such as those suffering from hematologic cancers and other patient populations for whom the current authorized COVID-19 vaccines are insufficient. In addition, GEO-CM04S1 is in a Phase 2 clinical trial evaluating the vaccine as a more robust, durable COVID-19 booster among healthy patients who previously received the mRNA vaccines. GeoVax has a leadership team who have driven significant value creation across multiple life science companies over the past several decades. For more information, visit our website: www.geovax.com.

Media Relations Contact:
Gina Cestari
6 Degrees
917-797-7904
gcestari@6degreespr.com
👍️0
TIZZUNI TIZZUNI 2 years ago
This Company is not garbage. This Company consists of dedicated, hard-working human beings, with the goal of producing effective medicines for the healing and survival of sick humanity.
👍️0
Trompete Trompete 2 years ago
is this garbage still listed on nasdaq? Cannot believe it
👍️0
carusso carusso 2 years ago
Agree.
👍️0
La Dolce Vita La Dolce Vita 2 years ago
You are welcome.

I watched the conference and it appears they have a chance of becoming a profitable biotech company.

The pipeline is quite robust, imo. Their approach of activating the T Cells stands to make their platform for vaccines be very valuable and very successful, if they can commercialize and develop their pipeline. All my opinion of course.
👍️0
carusso carusso 2 years ago
Thanks for sharing that link.
👍️0